EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

A Randomized, Double‐Blind, Parallel Design Thorough QT Study With a Nested Crossover to Compare the Cardiac Safety of Amiselimod With Placebo and Positive Control in Healthy Volunteers

Jimin Lee, Robert Lester, Terry O'Reilly, Ezra R Lowe, Neal E Slatkin, Howard Franklin, Robert J Israel

Clinical Pharmacology in Drug Development · 2023

DOI: 10.1002/cpdd.1210 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2023. Verfasst von Jimin Lee und 6 weiteren Autor:innen. Beteiligte Einrichtung: Bausch Health US, LLC, Bridgewater, New Jersey, USA. Hauptthemen laut MEDLINE: Fluoroquinolones, Long QT Syndrome. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Salix Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This double‐blind study evaluated the cardiac safety of amiselimod. Healthy adults (n = 190) were randomized (2:1:1) to receive (1) oral placebo (day −1), followed by oral amiselimod (days 1–26), which was upwardly titrated from 0.4 to 1.6 mg once daily to achieve steady‐state concentrations comparable with 0.4 (therapeutic) and 0.8 mg (supratherapeutic) once daily, and placebo (day 27); (2) placebo (day −1), oral moxifloxacin 400 mg (day 1; positive control), followed by placebo (days 1–27); or (3) placebo (days −1 to 26), followed by moxifloxacin 400 mg (day 27). No participant had a corrected QT interval by Fredericia (QTcF) >500 milliseconds or a change from baseline (dQTcF) >60 milliseconds. The upper limits of the 90%CIs for the differences in least‐squares mean difference in dQTcF between amiselimod and placebo on days 13 and 26 were

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FluoroquinolonesLong QT SyndromeAdultHumansMoxifloxacinElectrocardiographyDouble-Blind MethodHealthy VolunteersPropanolamines

Stichwörter der Autor:innen

QT/QTc studyS1P receptorS1P receptor modulatoramiselimodcardiac repolarizationlymphocytespharmacodynamicspharmacokinetics

Substanzen

MoxifloxacinFluoroquinolonesamiselimodPropanolamines

Autor:innen und Institutionen

  • Bausch Health US, LLC, Bridgewater, New Jersey, USA.
  • Celerion, Tempe, Arizona, USA.
  • Salix Pharmaceuticals, Bridgewater, New Jersey, USA.

Förderung

  • Salix Pharmaceuticals

Zitieren

APA

Lee, J., Lester, R., O'Reilly, T., Lowe, E. R., Slatkin, N. E., Franklin, H., & Israel, R. J. (2023). A Randomized, Double‐Blind, Parallel Design Thorough QT Study With a Nested Crossover to Compare the Cardiac Safety of Amiselimod With Placebo and Positive Control in Healthy Volunteers. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1210

Vancouver

Lee J, Lester R, O'Reilly T, Lowe ER, Slatkin NE, Franklin H, et al. A Randomized, Double‐Blind, Parallel Design Thorough QT Study With a Nested Crossover to Compare the Cardiac Safety of Amiselimod With Placebo and Positive Control in Healthy Volunteers. Clinical Pharmacology in Drug Development. 2023. doi:10.1002/cpdd.1210

BibTeX
@article{Lee2023,
  author = {Lee, Jimin and Lester, Robert and O'Reilly, Terry and Lowe, Ezra R and Slatkin, Neal E and Franklin, Howard and Israel, Robert J},
  title = {A Randomized, Double‐Blind, Parallel Design Thorough QT Study With a Nested Crossover to Compare the Cardiac Safety of Amiselimod With Placebo and Positive Control in Healthy Volunteers},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2023},
  doi = {10.1002/cpdd.1210}
}
Kostenlos starten →